The estimated Net Worth of Maiken Keson Brookes is at least $1.49 million dollars as of 29 January 2022. Ms. Brookes owns over 8,075 units of Rubius Therapeutics Inc stock worth over $670 and over the last 8 years she sold RUBY stock worth over $0. In addition, she makes $1,490,040 as Chief Legal Officer et Corporate Secretary at Rubius Therapeutics Inc.
Sign up
Ms. Brookes RUBY stock SEC Form 4 insiders trading
Maiken has made over 2 trades of the Rubius Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 8,075 units of RUBY stock worth $670 on 29 January 2022.
The largest trade she's ever made was exercising 25,000 units of Rubius Therapeutics Inc stock on 15 March 2021 worth over $192,500. On average, Maiken trades about 6,615 units every 64 days since 2017. As of 29 January 2022 she still owns at least 8,075 units of Rubius Therapeutics Inc stock.
You can see the complete history of Ms. Brookes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Maiken Keson-Brookes biography
Maiken Keson-Brookes is appointed as Chief Legal Officer, Corporate Secretary of the Company. Prior to joining our company, Ms. Keson-Brookes served as general counsel of Synlogic, Inc. from December 2017 to November 2019. Prior to Synlogic, Ms. Keson-Brookes served as general counsel of uniQure Inc. from December 2016 to July 2017. Prior to uniQure, Ms. Keson-Brookes served as general counsel of Forum Pharmaceuticals, Inc. from March 2011 to June 2016. She holds bachelor of laws and master of laws degrees from King's College London.
What is the salary of Maiken Brookes?
As the Chief Legal Officer et Corporate Secretary of Rubius Therapeutics Inc, the total compensation of Maiken Brookes at Rubius Therapeutics Inc is $1,490,040. There are 1 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.
How old is Maiken Brookes?
Maiken Brookes is 47, she's been the Chief Legal Officer et Corporate Secretary of Rubius Therapeutics Inc since 2019. There are 16 older and 1 younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.
What's Maiken Brookes's mailing address?
Maiken's mailing address filed with the SEC is C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE, MA, 02139.
Insiders trading at Rubius Therapeutics Inc
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz et Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
What does Rubius Therapeutics Inc do?
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
What does Rubius Therapeutics Inc's logo look like?
Complete history of Ms. Brookes stock trades at uniQure N.V et Rubius Therapeutics Inc
Rubius Therapeutics Inc executives and stock owners
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Pablo Cagnoni,
President, Chief Executive Officer, Director -
Maiken Keson-Brookes,
Chief Legal Officer, Corporate Secretary -
Dr. Pablo J. Cagnoni M.D., Ph.D.,
CEO, Pres & Director -
David Epstein,
Chairman of the Board -
Laurence A. Turka M.D.,
Chief Scientific Officer and Head of Research & Translational Medicine -
Natalie Holles,
Independent Director -
David R. Epstein B.Sc., M.B.A.,
Exec. Chairman -
Dannielle Appelhans,
Chief Operating Officer -
Anne Prener,
Independent Director -
Jonathan Symonds,
Independent Director -
Francis Cuss,
Independent Director -
Catherine Sohn,
Independent Director -
Noubar Afeyan,
Independent Director -
Michael Rosenblatt,
Independent Director -
Lori Melancon,
IR Contact Officer -
Christina Coughlin,
Chief Medical Officer -
Greg ..,
Chief Quality Officer -
Laurence Turka,
Chief Scientific Officer -
Kris Elverum,
Senior Vice President - Business Development and Strategy -
Jose Carmona,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer -
Jill Murray,
VP & Head of HR -
Marissa Hanify,
Director of Corp. Communications -
Maiken Keson-Brookes,
Chief Legal Officer & Corp. Sec. -
Elhan Webb C.F.A.,
VP of Investor Relations -
Mark J. Hernon,
Chief Information Officer -
Spencer Fisk,
Sr. VP & Chief Technical Operations Officer -
Jose I. Carmona,
CFO, Principal Accounting Officer & Treasurer -
Ventures Fund Iv General Pa...,
-
Susanne Schaffert,
Director -
Robert Langer,
Director -
Roger Pomerantz,
Director -
Ventures Fund Iv General Pa...,
-
Torben Straight Nissen,
President -
Christopher L. Carpenter,
Chief Medical Officer -
Dannielle Appelhans,
CEO and President